Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial
Status:
Completed
Trial end date:
2020-05-11
Target enrollment:
Participant gender:
Summary
Vitamin D promotes the differentiation of prostate cancer cells and maintains the
differentiated phenotype of prostate epithelial cells. The results of the investigators'
clinical studies indicate that vitamin D3 supplementation results in a decrease of positive
cancer cores at repeat biopsy in subjects with low-risk prostate cancer. The investigators
hypothesize that Veterans who have early-stage prostate cancer and who take vitamin D3 at
4000 international units per day (intervention group) will show an improvement in the number
of positive cores and in Gleason score at repeat biopsy, and a decreased likelihood of
undergoing definitive treatment (prostatectomy or radiation therapy), compared to Veteran
subjects taking placebo (control group).
Phase:
Phase 2
Details
Lead Sponsor:
VA Office of Research and Development
Collaborator:
Medical University of South Carolina
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins